Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Passage Bio, Inc. (PASG)
USD4.91
+0.47 (+10.59%)
US NASDAQ Healthcare Biotechnology
Address
One Commerce Square 19103
Philadelphia, PA, US
Philadelphia, PA, US
CEO
William Chou
Website
passagebio.com
IPO
2020-02-28
CIK 1787297 ISIN US7027122099
Description
Passage Bio, Inc. is a biopharmaceutical company dedicated to pioneering genetic therapies for conditions affecting the central nervous system. Their advanced pipeline includes PBGM01, designed to treat infantile GM1 gangliosidosis by utilizing a proprietary AAVhu68 capsid to deliver a functional GLB1 gene, which codes for the lysosomal acid beta-galactosidase enzyme, to both the brain and peripheral tissues. Another key program, PBFT02, employs an AAV1 capsid to introduce a functional granulin (GRN) gene, encoding progranulin (PGRN), to the brain as a treatment for FTD-GRN. Additionally, PBKR03 is under development for infantile Krabbe disease, leveraging a proprietary AAVhu68 capsid to deliver a functional GALC gene, responsible for producing the hydrolytic enzyme galactosylceramidase, to the brain and surrounding tissues. The company's portfolio also features PBML04 for metachromatic leukodystrophy, PBAL05 for amyotrophic lateral sclerosis, and PBCM06 for Charcot-Marie-Tooth Type 2A. Passage Bio maintains a significant research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program, alongside a development services and clinical supply agreement with Catalent Maryland, Inc. Established in 2017, the company's headquarters are located in Philadelphia, Pennsylvania.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD4.91
+0.47 (+10.59%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
113.8K
Beta
1.41
Float Shares
2.89M
Free Float %
90.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +9.74% | +33.66% | -48.94% | -37.34% | -35.29% | -53.22% | -6.44% | -73.20% | -98.25% | -98.76% | -98.76% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (11 ratings, all time)
Buy
Price Targets & DCF
Current price
4.91
Low
7.00
+42.6%
Consensus
10.00
+103.7%
Median
8.00
+62.9%
High
15.00
+205.5%
DCF (Unlevered)
6.70
+36.4%
DCF (Levered)
7.03
+43.1%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
20% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | -5 |
| Hold | 4 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 3 |
10.00
+103.7%
|
| Last Quarter | 3 |
10.00
+103.7%
|
| Last Year | 3 |
10.00
+103.7%
|
| All Time | 4 |
9.00
+83.3%
|
Quality scores
Altman Z-Score
-29.76
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
3 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
4 / 5
High
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+33.1% ★ Q1'26: +52.4% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+5.1% Q1'26: +3.2% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.57× Q1'26: -0.17× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 5 Rev. Ana. 4 EPS Ana. |
Dec 2027 4 Rev. Ana. 3 EPS Ana. |
Dec 2028 3 Rev. Ana. 3 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|
| Revenue |
—
|
—
est: 1.90M (-100.0%)
|
2.00M
2.00M – 2.00M
+5.3% YoY
|
45.01M
45.01M – 45.01M
+2,150.6% YoY
|
31.53M
31.53M – 31.53M
-30.0% YoY
|
15.03M
15.03M – 15.03M
-52.3% YoY
|
42.72M
42.72M – 42.72M
+184.2% YoY
|
| EBITDA |
-62.09M
|
-42.42M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-65.17M
|
-43.15M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-64.77M
est: -59.21M (-9.4%)
|
-45.52M
est: -28.50M (-59.7%)
|
-29.21M
-32.99M – -25.43M
-2.5% YoY
|
-24.87M
-29.70M – -20.04M
+14.9% YoY
|
-17.48M
-29.73M – -5.24M
+29.7% YoY
|
-22.43M
-22.43M – -22.43M
-28.3% YoY
|
-11.92M
-11.92M – -11.92M
+46.9% YoY
|
| SGA |
24.99M
|
19.88M
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-21.44
est: -19.70 (-8.8%)
|
-14.35
est: -9.83 (-46.0%)
|
-9.21
-10.40 – -8.02
+6.3% YoY
|
-7.84
-9.36 – -6.32
+14.9% YoY
|
-6.63
-9.37 – -1.65
+15.4% YoY
|
-7.07
-7.07 – -7.07
-6.6% YoY
|
-3.76
-3.76 – -3.76
+46.9% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-04-21 | Chardan Capital | Buy | Neutral | Downgrade |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-08 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-07 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-06 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-05 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-04 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-01 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-30 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-29 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-28 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-27 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C | 2/5 | 4/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
10
Total invested
6.67M
Insider transactions (90d)
0
Beneficial owners (>5%)
40
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Ryan Wilder | 6.10M | 9.90% | — | 6.10M | — | — | HC, IN | United States | 2024-11-14 | ↗ |
| 2 | Vestal Point Capital, LP | 6.10M | 9.90% | — | 6.10M | — | — | IA, PN | Delaware | 2024-11-14 | ↗ |
| 3 | OrbiMed Advisors LLC | 5.95M | 13.50% | — | 5.95M | — | 10.00 | IA | Delaware | 2020-03-09 | ↗ |
| 4 | OrbiMed Capital GP VII LLC | 5.95M | 13.50% | — | 5.95M | — | 10.00 | OO | Delaware | 2020-03-09 | ↗ |
| 5 | FHMLS IX, L.L.C. | 5.01M | 10.90% | — | 5.01M | — | 5.01M | OO | — | 2020-03-09 | ↗ |
| 6 | FHMLS IX, L.P. | 5.01M | 10.90% | — | 5.01M | — | 5.01M | PN | — | 2020-03-09 | ↗ |
| 7 | Frazier Life Sciences IX, L.P. | 5.01M | 10.90% | — | 5.01M | — | 5.01M | PN | — | 2020-03-09 | ↗ |
| 8 | James N. Topper | 5.01M | 10.90% | — | 5.01M | — | 5.01M | IN | — | 2020-03-09 | ↗ |
| 9 | Patrick J. Heron | 5.01M | 10.90% | — | 5.01M | — | 5.01M | IN | — | 2020-03-09 | ↗ |
| 10 | Lynx1 Capital Management LP | 4.85M | 8.70% | — | 4.85M | — | — | PN | Delaware | 2024-03-29 | ↗ |
| 11 | Weston Nichols | 4.85M | 8.70% | — | 4.85M | — | — | IN | Delaware | 2024-03-29 | ↗ |
| 12 | Abigail P. Johnson | 4.63M | 10.20% | — | — | 4.63M | — | IN | Delaware | 2020-06-10 | ↗ |
| 13 | Versant Venture Capital VI, L.P. | 4.03M | 9.20% | 4.03M | — | 4.03M | 11.00 | PN | — | 2020-03-13 | ↗ |
| 14 | Versant Ventures VI GP, L.P. | 4.03M | 9.20% | — | 4.03M | — | 11.00 | PN | — | 2020-03-13 | ↗ |
| 15 | Versant Ventures VI GP-GP, LLC | 4.03M | 9.20% | — | 4.03M | — | 11.00 | OO | — | 2020-03-13 | ↗ |
| 16 | David Kroin | 2.85M | 5.27% | — | 2.85M | — | — | HC, IN | United States | 2021-10-25 | ↗ |
| 17 | Deep Track Biotechnology Master Fund, Ltd. | 2.85M | 5.27% | — | 2.85M | — | — | CO | United States | 2021-10-25 | ↗ |
| 18 | Deep Track Capital, LP | 2.85M | 5.27% | — | 2.85M | — | — | IA, OO | United States | 2021-10-25 | ↗ |
| 19 | Yi Shi | 2.83M | 6.20% | — | 2.83M | — | 2.83M | IN | United States | 2021-02-09 | ↗ |
| 20 | FMR LLC | 2.67M | 4.93% | — | — | 2.67M | — | HC | United States of America | 2021-12-10 | ↗ |
| 21 | 10. | 2.62M | 5.90% | — | 2.62M | — | 2.62M | OO | State of Delaware | 2020-03-12 | ↗ |
| 22 | AI Passage LLC | 2.62M | 4.80% | — | 2.62M | — | 2.62M | OO | — | 2022-02-14 | ↗ |
| 23 | Access Industries Holdings LLC | 2.62M | 4.80% | — | 2.62M | — | 2.62M | OO | — | 2022-02-14 | ↗ |
| 24 | Access Industries Management, LLC | 2.62M | 4.80% | — | 2.62M | — | 2.62M | OO | — | 2022-02-14 | ↗ |
| 25 | Len Blavatnik | 2.62M | 4.80% | — | 2.62M | — | 2.62M | IN | — | 2022-02-14 | ↗ |
| 26 | Page 2 of 10 Pages | 2.50M | 4.70% | — | 2.50M | — | 2.50M | PN | — | 2021-02-11 | ↗ |
| 27 | Page 3 of 10 Pages | 2.50M | 4.70% | — | 2.50M | — | 2.50M | PN | — | 2021-02-11 | ↗ |
| 28 | Page 4 of 10 Pages | 2.50M | 4.70% | — | 2.50M | — | 2.50M | OO | — | 2021-02-11 | ↗ |
| 29 | Page 5 of 10 Pages | 2.50M | 4.70% | — | 2.50M | — | 2.50M | IN | — | 2021-02-11 | ↗ |
| 30 | Page 6 of 10 Pages | 2.50M | 4.70% | — | — | — | 2.50M | IN | — | 2021-02-11 | ↗ |
| 31 | LAV Prescience Limited (“LAVPRE”) | 2.42M | 5.30% | 2.42M | 2.42M | 2.42M | 2.42M | OO | British Virgin Islands | 2021-02-09 | ↗ |
| 32 | Vivo Capital VIII, LLC | 2.24M | 4.90% | 2.24M | — | 2.24M | — | OO | Delaware | 2020-03-06 | ↗ |
| 33 | (1) BlackRock, Inc. | 1.37M | 2.50% | 1.28M | — | 1.37M | — | HC | Delaware | 2022-07-08 | ↗ |
| 34 | OrbiMed Capital LLC | 1.02M | 2.30% | 1.02M | — | 1.02M | 10.00 | IA | Cayman Islands | 2020-03-09 | ↗ |
| 35 | Versant Vantage I GP, L.P. | 933.4K | 2.10% | — | 933.4K | — | 11.00 | PN | — | 2020-03-13 | ↗ |
| 36 | Versant Vantage I GP-GP, LLC | 933.4K | 2.10% | — | 933.4K | — | 11.00 | OO | — | 2020-03-13 | ↗ |
| 37 | Versant Vantage I, L.P. | 933.4K | 2.10% | 933.4K | — | 933.4K | 11.00 | PN | — | 2020-03-13 | ↗ |
| 38 | L.P. (“FUNDVSUBA”) | 410.0K | 0.90% | 410.0K | 410.0K | 410.0K | 410.0K | PN | United States | 2021-02-09 | ↗ |
| 39 | Vivo Opportunity, LLC | 213.5K | 0.50% | 213.5K | — | 213.5K | — | OO | Delaware | 2020-03-06 | ↗ |
| 40 | Vivo Capital IX, LLC. | 47.6K | 0.10% | 47.6K | — | 47.6K | — | OO | Delaware | 2020-03-06 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
10
-19 vs prev Q
New positions
4
Closed positions
23
Increased
5
Reduced
1
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | NANO CAP NEW MILLENNIUM GROWTH FUND L P | 10.0K +10.0K (+100.0%) | 118.00M +118.0M (+100.0%) | 0.32% +0.316 pp | 0.10% +0.101 pp | USD11.80 +0.0% | 1 qtrs NEW |
| 2 | LYNX1 CAPITAL MANAGEMENT LP | 623.7K +— (+0.0%) | 7.36M +2.4M (+46.9%) | 19.68% +0.000 pp | 1.49% +0.470 pp | USD8.03 +46.9% | 2 qtrs — |
| 3 | VESTAL POINT CAPITAL, LP | 305.0K +— (+0.0%) | 3.60M +1.1M (+46.9%) | 9.62% +0.000 pp | 0.12% +0.012 pp | USD8.03 +46.9% | 2 qtrs — |
| 4 | VANGUARD GROUP INC | 126.6K +9.6K (+8.2%) | 1.49M +557.0K (+59.4%) | 4.00% +0.303 pp | 0.00% +0.000 pp | USD8.32 +41.8% | 2 qtrs — |
| 5 | EVERSEPT PARTNERS, LP | 126.2K +126.2K (+100.0%) | 1.49M +1.5M (+100.0%) | 3.98% +3.983 pp | 0.08% +0.075 pp | USD11.80 +0.0% | 1 qtrs NEW |
| 6 | RENAISSANCE TECHNOLOGIES LLC | 109.1K +8.3K (+8.2%) | 1.29M +477.9K (+59.1%) | 3.44% +0.262 pp | 0.00% +0.001 pp | USD8.32 +41.8% | 2 qtrs — |
| 7 | ERSTE ASSET MANAGEMENT GMBH | 85.3K -37.5K (-30.6%) | 1.00M +4.6K (+0.5%) | 2.69% -1.184 pp | 0.01% -0.001 pp | USD8.03 +46.9% | 2 qtrs — |
| 8 | YIHENG CAPITAL MANAGEMENT, L.P. | 34.3K +34.3K (+100.0%) | 404.8K +404.8K (+100.0%) | 1.08% +1.082 pp | 0.08% +0.082 pp | USD11.80 +0.0% | 1 qtrs NEW |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 31.4K +4.1K (+15.1%) | 370.6K +152.0K (+69.5%) | 0.99% +0.130 pp | 0.00% +0.000 pp | USD8.52 +38.5% | 2 qtrs — |
| 10 | BLACKROCK, INC. | 28.9K -846.0 (-2.8%) | 341.1K +102.2K (+42.8%) | 0.91% -0.027 pp | 0.00% +0.000 pp | USD8.03 +46.9% | 2 qtrs — |
| 11 | ACADIAN ASSET MANAGEMENT LLC | 24.2K -1.4K (-5.4%) | 284.0K +80.0K (+39.2%) | 0.76% -0.043 pp | 0.00% +0.000 pp | USD8.03 +46.9% | 2 qtrs — |
| 12 | CITADEL ADVISORS LLC | 17.7K -1.4K (-7.5%) | 208.4K +55.5K (+36.3%) | 0.56% -0.045 pp | 0.00% +0.000 pp | USD8.03 +46.9% | 2 qtrs — |
| 13 | NORTHERN TRUST CORP | 14.2K +14.2K (+100.0%) | 167.8K +167.8K (+100.0%) | 0.45% +0.449 pp | 0.00% +0.000 pp | USD11.80 +0.0% | 1 qtrs NEW |
| 14 | QUADRATURE CAPITAL LTD | 12.6K +12.6K (+100.0%) | 148.4K +148.4K (+100.0%) | 0.40% +0.397 pp | 0.00% +0.002 pp | USD11.80 +0.0% | 1 qtrs NEW |
| 15 | SQUAREPOINT OPS LLC | 10.8K -12.7K (-54.0%) | 127.4K -60.8K (-32.3%) | 0.34% -0.401 pp | 0.00% 0.000 pp | USD8.03 +46.9% | 2 qtrs — |
| 16 | FIDUCIARY TRUST CO | 10.8K +— (+0.0%) | 126.9K +40.5K (+46.9%) | 0.34% +0.000 pp | 0.00% +0.001 pp | USD8.03 +46.9% | 2 qtrs — |
| 17 | MORGAN STANLEY | 4.3K +3.9K (+1,164.8%) | 50.4K +47.7K (+1,758.7%) | 0.13% +0.124 pp | 0.00% +0.000 pp | USD11.50 +2.6% | 2 qtrs — |
| 18 | UBS GROUP AG | 1.4K +1.4K (+8,382.4%) | 17.0K +16.9K (+12,320.4%) | 0.05% +0.045 pp | 0.00% +0.000 pp | USD11.76 +0.3% | 2 qtrs — |
| 19 | ROCKEFELLER CAPITAL MANAGEMENT L.P. | 500.00 +500.0 (+100.0%) | 5.9K +5.9K (+100.0%) | 0.02% +0.016 pp | 0.00% +0.000 pp | USD11.80 +0.0% | 1 qtrs NEW |
| 20 | SBI SECURITIES CO., LTD. | 142.00 +— (+0.0%) | 1.7K +536.0 (+47.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.39 +2,925.6% | 3 qtrs — |
| 21 | BANK OF AMERICA CORP /DE/ | 28.00 +— (+0.0%) | 331.00 +106.0 (+47.1%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD8.00 +47.5% | 2 qtrs — |
| 22 | ADVISOR GROUP HOLDINGS, INC. | 20.00 +— (+0.0%) | 236.00 +95.0 (+67.4%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD8.00 +47.5% | 2 qtrs — |
| 23 | PARALLEL ADVISORS, LLC | 16.00 +— (+0.0%) | 189.00 +61.0 (+47.7%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD8.00 +47.5% | 2 qtrs — |
| 24 | JPMORGAN CHASE & CO | 15.00 +— (+0.0%) | 177.00 +57.0 (+47.5%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD8.00 +47.5% | 2 qtrs — |
| 25 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | 2.00 +— (+0.0%) | 163.00 +147.0 (+918.8%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD8.00 +47.5% | 2 qtrs — |
| 26 | BNP PARIBAS ARBITRAGE, SNC | 12.00 +— (+0.0%) | 142.00 +46.0 (+47.9%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD8.00 +47.5% | 2 qtrs — |
| 27 | LRI INVESTMENTS, LLC | 12.00 +— (+0.0%) | 142.00 +46.0 (+47.9%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.33 +3,475.8% | 3 qtrs — |
| 28 | HARBOUR INVESTMENTS, INC. | 3.00 +— (+0.0%) | 35.00 +11.0 (+45.8%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD8.00 +47.5% | 2 qtrs — |
| 29 | ORBIMED ADVISORS LLC | — -59.0K (-100.0%) | — -474.1K (-100.0%) | 0.00% -1.863 pp | 0.00% -0.011 pp | USD— | 2 qtrs SOLD |
| 30 | CITIGROUP INC | — -77.0 (-100.0%) | — -617.0 (-100.0%) | 0.00% -0.002 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 31 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | — -20.8K (-100.0%) | — -166.6K (-100.0%) | 0.00% -0.657 pp | 0.00% -0.004 pp | USD— | 2 qtrs SOLD |
| 32 | MAI CAPITAL MANAGEMENT | — -200.0 (-100.0%) | — -1.6K (-100.0%) | 0.00% -0.006 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 33 | TANG CAPITAL MANAGEMENT LLC | — -75.0K (-100.0%) | — -602.3K (-100.0%) | 0.00% -2.367 pp | 0.00% -0.023 pp | USD— | 2 qtrs SOLD |
| 34 | TOWER RESEARCH CAPITAL LLC (TRC) | — -289.0 (-100.0%) | — -2.3K (-100.0%) | 0.00% -0.009 pp | 0.00% 0.000 pp | USD— | 2 qtrs SOLD |
| 35 | BARCLAYS PLC | — -13.2K (-100.0%) | — -9.2K (-100.0%) | 0.00% -0.415 pp | 0.00% +0.000 pp | USD— | 16 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 13 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 198.5K | 0.05% |
| 2 | Dimensional - US Core Equity 1 ETF DCOR | 0.00% | 6.0K | 0.14% |
| 3 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | 2.6K | 0.17% |
| 4 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 195.31 | 0.17% |
| 5 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | 963.00 | 0.03% |
| 6 | Vanguard Total Stock Market ETF VTI | 0.00% | 452.0K | 0.03% |
| 7 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 990.02 | 0.22% |
| 8 | Dimensional - US Core Equity 2 ETF DFAC | 0.00% | 3.7K | 0.17% |
| 9 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 539.45 | 0.22% |
| 10 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 217.97 | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
1.00
Neutral
Ratio by volume
3.00
Bullish
Buys
4
Sells
4
Shares acquired
88.6K
Shares disposed
21.1K
Cash buys
—
Cash sales
2.00
Net activity
+67,472
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-16 | Chou William | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 58,000 | 7.64 | 443.1K | 58,000 | D | ↗ |
| 2026-03-16 | Borthwick Kathleen | Officer | A-Award | A | Employee Stock Option (right to buy) | 15,610 | 7.64 | 119.3K | 15,610 | D | ↗ |
| 2026-01-08 | Chou William | Director / Officer | M-Exempt | A | Common Stock | 10,000 | 0.00 | — | 10,600 | D | ↗ |
| 2026-01-08 | Borthwick Kathleen | Officer | M-Exempt | A | Common Stock | 5,000 | 0.00 | — | 7,464 | D | ↗ |
| 2025-09-15 | Lynx1 Capital Management LP | 10% Owner | P-Purchase | A | Common Stock | 11,900 | 6.99 | 83.2K | 623,704 | I | ↗ |
| 2025-09-12 | Lynx1 Capital Management LP | 10% Owner | P-Purchase | A | Common Stock | 19,783 | 6.99 | 138.3K | 611,804 | I | ↗ |
| 2025-09-11 | Lynx1 Capital Management LP | 10% Owner | P-Purchase | A | Common stock, $0.0001 par value per share (Common Stock) | 325 | 6.96 | 2.3K | 592,021 | I | ↗ |
| 2025-07-24 | Lynx1 Capital Management LP | 10% Owner | P-Purchase | A | Common Stock | 66,423 | 5.71 | 379.5K | 591,696 | I | ↗ |
| 2025-07-23 | Lynx1 Capital Management LP | 10% Owner | P-Purchase | A | Common Stock | 49,302 | 5.74 | 283.0K | 525,273 | I | ↗ |
| 2025-07-22 | Lynx1 Capital Management LP | 10% Owner | P-Purchase | A | Common stock, $0.0001 par value per share ("Common Stock") | 13,123 | 5.44 | 71.3K | 475,971 | I | ↗ |
| 2025-06-26 | ORBIMED ADVISORS LLC | 10% Owner | S-Sale | D | Common Stock | 213,257 | 0.33 | 70.4K | 6,066,343 | I | ↗ |
| 2025-06-25 | ORBIMED ADVISORS LLC | 10% Owner | S-Sale | D | Common Stock | 138,800 | 0.33 | 45.8K | 6,279,600 | I | ↗ |
| 2025-06-24 | ORBIMED ADVISORS LLC | 10% Owner | S-Sale | D | Common Stock | 231,600 | 0.35 | 81.1K | 6,418,400 | I | ↗ |
| 2025-05-28 | Sondhi Dolan | Director | A-Award | A | Director Stock Option (right to buy) | 201,857 | 0.36 | 72.6K | 201,857 | D | ↗ |
| 2025-05-28 | Porter Derrell | Director | A-Award | A | Director Stock Option (right to buy) | 201,857 | 0.36 | 72.6K | 201,857 | D | ↗ |
| 2025-05-28 | Kassberg Thomas Richard | Director | A-Award | A | Director Stock Option (right to buy) | 143,789 | 0.36 | 51.7K | 143,789 | D | ↗ |
| 2025-05-28 | Kapadia Sandip | Director | A-Award | A | Director Stock Option (right to buy) | 201,857 | 0.36 | 72.6K | 201,857 | D | ↗ |
| 2025-05-28 | Islam Saqib | Director | A-Award | A | Director Stock Option (right to buy) | 201,857 | 0.36 | 72.6K | 201,857 | D | ↗ |
| 2025-05-28 | GOWEN MAXINE | Director | A-Award | A | Director Stock Option (right to buy) | 201,857 | 0.36 | 72.6K | 201,857 | D | ↗ |
| 2025-05-28 | Countouriotis Athena | Director | A-Award | A | Director Stock Option (right to buy) | 201,857 | 0.36 | 72.6K | 201,857 | D | ↗ |
| 2025-04-24 | ORBIMED ADVISORS LLC | 10% Owner | S-Sale | D | Common Stock | 68,195 | 0.32 | 21.8K | 6,650,000 | I | ↗ |
| 2025-04-23 | ORBIMED ADVISORS LLC | 10% Owner | S-Sale | D | Common Stock | 89,328 | 0.34 | 30.4K | 6,718,195 | I | ↗ |
| 2025-04-22 | ORBIMED ADVISORS LLC | 10% Owner | S-Sale | D | Common Stock | 78,049 | 0.34 | 26.5K | 6,807,523 | I | ↗ |
| 2025-04-17 | ORBIMED ADVISORS LLC | 10% Owner | S-Sale | D | Common Stock | 77,090 | 0.33 | 25.4K | 6,885,572 | I | ↗ |
| 2025-04-16 | ORBIMED ADVISORS LLC | 10% Owner | S-Sale | D | Common Stock | 61,638 | 0.33 | 20.3K | 6,962,662 | I | ↗ |
| 2025-04-15 | ORBIMED ADVISORS LLC | 10% Owner | S-Sale | D | Common Stock | 10,326 | 0.38 | 3.9K | 7,024,300 | I | ↗ |
| 2025-03-15 | Chou William | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 779,533 | 0.39 | 301.7K | 779,533 | D | ↗ |
| 2025-03-15 | Cale Edgar B. | Officer | A-Award | A | Employee Stock Option (right to buy) | 278,386 | 0.39 | 107.7K | 278,386 | D | ↗ |
| 2025-03-15 | Borthwick Kathleen | Officer | A-Award | A | Employee Stock Option (right to buy) | 278,386 | 0.39 | 107.7K | 278,386 | D | ↗ |
| 2025-02-11 | Borthwick Kathleen | Officer | S-Sale | D | Common Stock | 3,183 | 0.53 | 1.7K | 41,283 | D | ↗ |
| 2025-02-10 | Borthwick Kathleen | Officer | M-Exempt | A | Common Stock | 8,000 | 0.00 | — | 44,466 | D | ↗ |
| 2025-01-15 | Chou William | Director / Officer | A-Award | A | Restricted Stock Unit | 20,000 | 0.00 | — | 20,000 | D | ↗ |
| 2025-01-15 | Borthwick Kathleen | Officer | A-Award | A | Restricted Stock Unit | 10,000 | 0.00 | — | 10,000 | D | ↗ |
| 2025-01-14 | ORBIMED ADVISORS LLC | 10% Owner | S-Sale | D | Common Stock | 79,024 | 0.60 | 47.4K | 7,034,626 | I | ↗ |
| 2025-01-13 | ORBIMED ADVISORS LLC | 10% Owner | S-Sale | D | Common Stock | 17,986 | 0.64 | 11.5K | 7,113,650 | I | ↗ |
| 2025-01-10 | ORBIMED ADVISORS LLC | 10% Owner | S-Sale | D | Common Stock | 126,209 | 0.66 | 83.3K | 7,131,636 | I | ↗ |
| 2025-01-08 | ORBIMED ADVISORS LLC | 10% Owner | S-Sale | D | Common Stock | 75,007 | 0.68 | 51.0K | 7,257,845 | I | ↗ |
| 2025-01-07 | ORBIMED ADVISORS LLC | 10% Owner | S-Sale | D | Common Stock | 52,536 | 0.71 | 37.3K | 7,332,852 | I | ↗ |
| 2025-01-06 | ORBIMED ADVISORS LLC | 10% Owner | S-Sale | D | Common Stock | 19,481 | 0.77 | 15.0K | 7,385,388 | I | ↗ |
| 2024-12-27 | Lynx1 Capital Management LP | 10% Owner | P-Purchase | A | Common stock, $0.0001 par value per share | 373,645 | 0.65 | 241.0K | 9,256,953 | I | ↗ |
| 2024-12-20 | ORBIMED ADVISORS LLC | 10% Owner | S-Sale | D | Common Stock | 230,321 | 0.60 | 138.2K | 7,404,869 | I | ↗ |
| 2024-12-11 | ORBIMED ADVISORS LLC | 10% Owner | S-Sale | D | Common Stock | 80 | 0.80 | 64.00 | 7,635,190 | I | ↗ |
| 2024-12-10 | ORBIMED ADVISORS LLC | 10% Owner | S-Sale | D | Common Stock | 8,015 | 0.80 | 6.4K | 7,635,270 | I | ↗ |
| 2024-12-09 | ORBIMED ADVISORS LLC | 10% Owner | S-Sale | D | Common Stock | 54,181 | 0.84 | 45.5K | 7,643,285 | I | ↗ |
| 2024-12-06 | ORBIMED ADVISORS LLC | 10% Owner | S-Sale | D | Common Stock | 20,903 | 0.82 | 17.1K | 7,697,466 | I | ↗ |
| 2024-12-04 | ORBIMED ADVISORS LLC | 10% Owner | S-Sale | D | Common Stock | 76,200 | 0.79 | 60.2K | 7,718,369 | I | ↗ |
| 2024-11-27 | Lynx1 Capital Management LP | 10% Owner | P-Purchase | A | Common Stock | 29,300 | 0.67 | 19.7K | 8,883,308 | I | ↗ |
| 2024-11-26 | Lynx1 Capital Management LP | 10% Owner | P-Purchase | A | Common Stock | 167,055 | 0.71 | 118.2K | 8,854,008 | I | ↗ |
| 2024-11-25 | Lynx1 Capital Management LP | 10% Owner | P-Purchase | A | Common stock, $0.0001 par value per share ("Common Stock") | 259,998 | 0.56 | 146.7K | 8,686,953 | I | ↗ |
| 2024-09-30 | Kassberg Thomas Richard | Director | A-Award | A | Employee Stock Option (right to buy) | 174,139 | 0.70 | 121.9K | 174,139 | D | ↗ |
| 2024-09-30 | Cale Edgar B. | Officer | A-Award | A | Employee Stock Option (right to buy) | 50,000 | 0.70 | 35.0K | 50,000 | D | ↗ |
| 2024-09-19 | ORBIMED ADVISORS LLC | 10% Owner | S-Sale | D | Common Stock | 39,300 | 0.71 | 27.9K | 7,794,569 | I | ↗ |
| 2024-09-18 | ORBIMED ADVISORS LLC | 10% Owner | S-Sale | D | Common Stock | 25,631 | 0.73 | 18.7K | 7,833,869 | — | ↗ |
| 2024-09-17 | ORBIMED ADVISORS LLC | 10% Owner | S-Sale | D | Common Stock | 111,400 | 0.73 | 81.3K | 7,859,500 | — | ↗ |
| 2024-09-16 | ORBIMED ADVISORS LLC | 10% Owner | S-Sale | D | Common Stock | 63,100 | 0.74 | 46.7K | 7,970,900 | — | ↗ |
| 2024-09-10 | Kassberg Thomas Richard | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-08-07 | Lynx1 Capital Management LP | 10% Owner | — | I | Common stock, $0.0001 par value per share | 0 | 0.00 | — | 8,426,955 | — | ↗ |
| 2024-05-21 | Sondhi Dolan | Director | A-Award | A | Director Stock Option (right to buy) | 39,092 | 1.28 | 50.0K | 39,092 | — | ↗ |
| 2024-05-21 | Porter Derrell | Director | A-Award | A | Director Stock Option (right to buy) | 47,693 | 1.28 | 61.0K | 47,693 | — | ↗ |
| 2024-05-21 | Kapadia Sandip | Director | A-Award | A | Director Stock Option (right to buy) | 47,693 | 1.28 | 61.0K | 47,693 | — | ↗ |
| 2024-05-21 | Islam Saqib | Director | A-Award | A | Director Stock Option (right to buy) | 47,693 | 1.28 | 61.0K | 47,693 | — | ↗ |
| 2024-05-21 | GOWEN MAXINE | Director | A-Award | A | Director Stock Option (right to buy) | 47,693 | 1.28 | 61.0K | 47,693 | — | ↗ |
| 2024-05-21 | Countouriotis Athena | Director | A-Award | A | Director Stock Option (right to buy) | 47,693 | 1.28 | 61.0K | 47,693 | — | ↗ |
| 2024-03-15 | Forman Mark S | Officer | A-Award | A | Employee Stock Option (right to buy) | 203,000 | 1.50 | 304.5K | 203,000 | — | ↗ |
| 2024-03-15 | Chou William | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 575,000 | 1.50 | 862.5K | 575,000 | — | ↗ |
| 2024-03-15 | Cale Edgar B. | Officer | A-Award | A | Employee Stock Option (right to buy) | 203,000 | 1.50 | 304.5K | 203,000 | — | ↗ |
| 2024-03-15 | Borthwick Kathleen | Officer | A-Award | A | Employee Stock Option (right to buy) | 227,000 | 1.50 | 340.5K | 227,000 | — | ↗ |
| 2024-02-13 | Forman Mark S | Officer | S-Sale | D | Common Stock | 1,638 | 0.97 | 1.6K | 48,631 | — | ↗ |
| 2024-02-13 | Borthwick Kathleen | Officer | S-Sale | D | Common Stock | 1,470 | 0.97 | 1.4K | 28,466 | — | ↗ |
| 2024-02-10 | Forman Mark S | Officer | M-Exempt | A | Common Stock | 5,000 | 0.00 | — | 50,269 | — | ↗ |
| 2024-02-10 | Borthwick Kathleen | Officer | M-Exempt | D | Restricted Stock Unit | 4,000 | 0.00 | — | 8,000 | — | ↗ |
| 2024-01-02 | Forman Mark S | Officer | S-Sale | D | Common Stock | 15,813 | 0.91 | 14.4K | 45,269 | — | ↗ |
| 2024-01-02 | Cale Edgar B. | Officer | S-Sale | D | Common Stock | 15,813 | 0.91 | 14.4K | 45,995 | — | ↗ |
| 2024-01-02 | Borthwick Kathleen | Officer | S-Sale | D | Common Stock | 10,672 | 0.91 | 9.7K | 25,936 | — | ↗ |
| 2023-12-31 | Forman Mark S | Officer | M-Exempt | D | Restricted Stock Unit | 50,000 | 0.00 | — | 0 | — | ↗ |
| 2023-12-31 | Cale Edgar B. | Officer | M-Exempt | A | Common Stock | 50,000 | 0.00 | — | 61,808 | — | ↗ |
| 2023-12-31 | Borthwick Kathleen | Officer | M-Exempt | A | Common Stock | 30,000 | 0.00 | — | 36,608 | — | ↗ |
| 2023-07-28 | Sondhi Dolan | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-07-28 | King Simona | Officer | S-Sale | D | Common Stock | 11,453 | 0.88 | 10.1K | 23,994 | — | ↗ |
| 2023-07-28 | Borthwick Kathleen | Officer | — | D | Employee Stock Option (right to buy) | 56,000 | 6.75 | 378.0K | 0 | — | ↗ |
| 2023-07-27 | Sondhi Dolan | Director | A-Award | A | Director Stock Option (right to buy) | 48,000 | 0.85 | 40.7K | 48,000 | — | ↗ |
| 2023-06-28 | ORBIMED ADVISORS LLC | 10% Owner | P-Purchase | A | Common Stock | 575,195 | 0.84 | 483.2K | 8,034,000 | — | ↗ |
| 2023-06-27 | ORBIMED ADVISORS LLC | 10% Owner | P-Purchase | A | Common Stock | 617,382 | 0.84 | 518.6K | 7,458,805 | — | ↗ |
| 2023-06-16 | Fotopoulos Alexandros | Officer | S-Sale | D | Common Stock | 4,052 | 0.93 | 3.8K | 28,693 | — | ↗ |
| 2023-06-15 | Fotopoulos Alexandros | Officer | M-Exempt | A | Common Stock | 12,500 | 0.00 | — | 32,745 | — | ↗ |
| 2023-05-25 | Woiwode Thomas | Director / 10% Owner | A-Award | A | Director Stock Option (Right to Buy) | 24,000 | 1.00 | 24.0K | 24,000 | — | ↗ |
| 2023-05-25 | Porter Derrell | Director | A-Award | A | Director Stock Option (Right to Buy) | 24,000 | 1.00 | 24.0K | 24,000 | — | ↗ |
| 2023-05-25 | Kapadia Sandip | Director | A-Award | A | Director Stock Option (Right to Buy) | 24,000 | 1.00 | 24.0K | 24,000 | — | ↗ |
| 2023-05-25 | Kamarck Michael E. | Director | A-Award | A | Director Stock Option (Right to Buy) | 21,567 | 1.00 | 21.6K | 21,567 | — | ↗ |
| 2023-05-25 | Islam Saqib | Director | A-Award | A | Director Stock Option (Right to Buy) | 24,000 | 1.00 | 24.0K | 24,000 | — | ↗ |
| 2023-05-25 | GOWEN MAXINE | Director | A-Award | A | Director Stock Option (Right to Buy) | 24,000 | 1.00 | 24.0K | 24,000 | — | ↗ |
| 2023-05-25 | Countouriotis Athena | Director | A-Award | A | Director Stock Option (Right to Buy) | 24,000 | 1.00 | 24.0K | 24,000 | — | ↗ |
| 2023-04-18 | King Simona | Officer | M-Exempt | D | Restricted Stock Units | 6,250 | 0.00 | — | 18,750 | — | ↗ |
| 2023-03-15 | King Simona | Officer | A-Award | A | Employee Stock Option (right to buy) | 140,000 | 1.08 | 151.2K | 140,000 | — | ↗ |
| 2023-03-15 | Fotopoulos Alexandros | Officer | A-Award | A | Employee Stock Option (right to buy) | 175,000 | 1.08 | 189.0K | 175,000 | — | ↗ |
| 2023-03-15 | Forman Mark S | Officer | A-Award | A | Employee Stock Option (right to buy) | 175,000 | 1.08 | 189.0K | 175,000 | — | ↗ |
| 2023-03-15 | Chou William | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 608,615 | 1.08 | 657.3K | 608,615 | — | ↗ |
| 2023-03-15 | Cale Edgar B. | Officer | A-Award | A | Employee Stock Option (right to buy) | 175,000 | 1.08 | 189.0K | 175,000 | — | ↗ |
| 2022-12-01 | Kapadia Sandip | Director | S-Sale | D | Common Stock | 5,000 | 1.19 | 6.0K | 0 | — | ↗ |
| 2022-11-22 | Fotopoulos Alexandros | Officer | M-Exempt | D | Restricted Stock Units | 12,500 | 0.00 | — | 37,500 | — | ↗ |
| 2022-11-10 | King Simona | Officer | A-Award | A | Restricted Stock Unit | 50,000 | 0.00 | — | 50,000 | — | ↗ |
| 2022-11-10 | Fotopoulos Alexandros | Officer | A-Award | A | Restricted Stock Unit | 50,000 | 0.00 | — | 50,000 | — | ↗ |
| 2022-11-10 | Forman Mark S | Officer | A-Award | A | Restricted Stock Unit | 50,000 | 0.00 | — | 50,000 | — | ↗ |
| 2022-11-10 | Cale Edgar B. | Officer | A-Award | A | Restricted Stock Unit | 50,000 | 0.00 | — | 50,000 | — | ↗ |
| 2022-10-10 | Chou William | Officer | A-Award | A | Employee Stock Option (right to buy) | 885,000 | 0.00 | — | 885,000 | — | ↗ |
| 2022-09-19 | Toernsen Monika Maria | Officer | S-Sale | D | Common Stock | 1,681 | 1.51 | 2.5K | 3,319 | — | ↗ |
| 2022-09-15 | Toernsen Monika Maria | Officer | M-Exempt | A | Common Stock | 5,000 | 0.00 | — | 5,000 | — | ↗ |
| 2022-07-05 | Kamarck Michael E. | Director | A-Award | A | Stock Option (right to buy) | 48,000 | 0.00 | — | 48,000 | — | ↗ |
| 2022-07-02 | Kamarck Michael E. | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-06-13 | Toernsen Monika Maria | Officer | A-Award | A | Employee Stock Option (right to buy) | 101,000 | 0.00 | — | 101,000 | — | ↗ |
| 2022-06-13 | King Simona | Officer | A-Award | A | Employee Stock Option (right to buy) | 159,000 | 0.00 | — | 159,000 | — | ↗ |
| 2022-06-13 | Fotopoulos Alexandros | Officer | A-Award | A | Employee Stock Option (right to buy) | 200,000 | 0.00 | — | 200,000 | — | ↗ |
| 2022-06-13 | Forman Mark S | Officer | A-Award | A | Employee Stock Option (right to buy) | 136,000 | 0.00 | — | 136,000 | — | ↗ |
| 2022-06-13 | Cale Edgar B. | Officer | A-Award | A | Employee Stock Option (right to buy) | 106,000 | 2.29 | 242.7K | 106,000 | — | ↗ |
| 2022-05-31 | GOWEN MAXINE | Director | A-Award | A | Stock Option (Right to Buy) | 40,000 | 1.80 | 72.0K | 40,000 | — | ↗ |
| 2022-05-31 | Cale Edgar B. | Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 0.00 | — | 100,000 | — | ↗ |
| 2022-05-27 | Goldsmith Bruce A | Officer | A-Award | A | Stock Option (Right to Buy) | 100,000 | 0.00 | — | 100,000 | — | ↗ |
| 2022-05-26 | Woiwode Thomas | Director | A-Award | A | Director Stock Option (Right to Buy) | 24,000 | 0.00 | — | 24,000 | — | ↗ |
| 2022-05-26 | Porter Derrell | Director | A-Award | A | Director Stock Option (Right to Buy) | 24,000 | 0.00 | — | 24,000 | — | ↗ |
| 2022-05-26 | Kapadia Sandip | Director | A-Award | A | Director Stock Option (Right to Buy) | 24,000 | 0.00 | — | 24,000 | — | ↗ |
| 2022-05-26 | Islam Saqib | Director | A-Award | A | Director Stock Option (Right to Buy) | 24,000 | 0.00 | — | 24,000 | — | ↗ |
| 2022-05-26 | GOWEN MAXINE | Director | A-Award | A | Director Stock Option (Right to Buy) | 24,000 | 1.76 | 42.2K | 24,000 | — | ↗ |
| 2022-05-26 | Countouriotis Athena | Director | A-Award | A | Director Stock Option (Right to Buy) | 24,000 | 1.76 | 42.2K | 24,000 | — | ↗ |
| 2022-05-04 | ORBIMED ADVISORS LLC | 10% Owner | P-Purchase | A | Common Stock | 303,500 | 1.94 | 588.8K | 6,841,423 | — | ↗ |
| 2022-05-03 | OrbiMed Capital GP VII LLC | Director | P-Purchase | A | Common Stock | 221,500 | 1.93 | 427.5K | 6,537,923 | — | ↗ |
| 2022-05-03 | ORBIMED ADVISORS LLC | 10% Owner | P-Purchase | A | Common Stock | 221,500 | 1.93 | 427.5K | 6,537,923 | — | ↗ |
| 2022-04-18 | King Simona | Officer | A-Award | A | Restricted Stock Unit | 25,000 | 0.00 | — | 25,000 | — | ↗ |
| 2022-04-18 | Forman Mark S | Officer | A-Award | A | Employee Stock Options (right to buy) | 136,000 | 0.00 | — | 136,000 | — | ↗ |
| 2022-03-30 | Forman Mark S | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2022-03-21 | Goldsmith Bruce A | Officer | P-Purchase | A | Common Stock | 10,000 | 3.15 | 31.5K | 15,983 | — | ↗ |
| 2022-02-10 | Toernsen Monika Maria | Officer | A-Award | A | Stock Option (right to buy) | 101,000 | 4.52 | 456.5K | 101,000 | — | ↗ |
| 2022-02-10 | Salinas Eliseo Oreste | Officer | A-Award | A | Stock Option (right to buy) | 157,500 | 4.52 | 711.9K | 157,500 | — | ↗ |
| 2022-02-10 | King Simona | Officer | A-Award | A | Stock Option (right to buy) | 159,000 | 4.52 | 718.7K | 159,000 | — | ↗ |
| 2022-02-10 | Goldsmith Bruce A | Director / Officer | A-Award | A | Stock Option (right to buy) | 400,000 | 4.52 | 1.81M | 400,000 | — | ↗ |
| 2022-02-10 | Fotopoulos Alexandros | Officer | A-Award | A | Stock Option (right to buy) | 163,900 | 4.52 | 740.8K | 163,900 | — | ↗ |
| 2022-02-10 | Forman Mark S | Officer | A-Award | A | Restricted Stock Unit | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2022-02-10 | Cale Edgar B. | Officer | A-Award | A | Stock Option (right to buy) | 106,000 | 4.52 | 479.1K | 106,000 | — | ↗ |
| 2022-01-20 | ORBIMED ADVISORS LLC | 10% Owner | P-Purchase | A | Common Stock | 50,800 | 5.00 | 254.0K | 6,316,423 | — | ↗ |
| 2022-01-19 | ORBIMED ADVISORS LLC | 10% Owner | P-Purchase | A | Common Stock | 43,300 | 5.11 | 221.3K | 6,265,623 | — | ↗ |
| 2022-01-18 | ORBIMED ADVISORS LLC | 10% Owner | P-Purchase | A | Common Stock | 114,700 | 5.46 | 626.3K | 6,222,323 | — | ↗ |
| 2022-01-14 | ORBIMED ADVISORS LLC | 10% Owner | P-Purchase | A | Common Stock | 10,300 | 5.60 | 57.7K | 6,107,623 | — | ↗ |
| 2022-01-13 | ORBIMED ADVISORS LLC | 10% Owner | P-Purchase | A | Common Stock | 41,800 | 5.52 | 230.7K | 6,097,323 | — | ↗ |
| 2022-01-12 | ORBIMED ADVISORS LLC | 10% Owner | P-Purchase | A | Common Stock | 100,000 | 5.65 | 565.0K | 6,055,523 | — | ↗ |
| 2022-01-11 | ORBIMED ADVISORS LLC | 10% Owner | P-Purchase | A | Common Stock | 8,200 | 5.53 | 45.3K | 5,955,523 | — | ↗ |
| 2021-12-08 | Quigley Jill M. | Officer | M-Exempt | A | Common Stock | 71,975 | 0.23 | 16.6K | 368,754 | — | ↗ |
| 2021-08-23 | King Simona | Officer | A-Award | A | Employee Stock Option (Right to Buy) | 360,000 | 11.43 | 4.11M | 360,000 | — | ↗ |
| 2021-08-16 | Forman Mark S | Officer | A-Award | A | Employee Stock Option (right to buy) | 130,000 | 10.84 | 1.41M | 130,000 | — | ↗ |
| 2021-07-19 | Toernsen Monika Maria | Officer | A-Award | A | Restricted Stock Units | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2021-05-30 | Burkavage Brian | Officer | — | D | Employee Stock Option (Right to Buy) | 24,000 | 22.63 | 543.1K | 0 | — | ↗ |
| 2021-05-27 | Yamada Tadataka | Director | A-Award | A | Director Stock Option (Right to Buy) | 16,918 | 13.83 | 234.0K | 16,918 | — | ↗ |
| 2021-05-27 | Woiwode Thomas | Director / 10% Owner | A-Award | A | Director Stock Option (Right to Buy) | 16,918 | 13.83 | 234.0K | 16,918 | — | ↗ |
| 2021-05-27 | Ratcliffe Liam | Director | A-Award | A | Director Stock Option (Right to Buy) | 16,918 | 13.83 | 234.0K | 16,918 | — | ↗ |
| 2021-05-27 | Porter Derrell | Director | A-Award | A | Director Stock Option (Right to Buy) | 33,836 | 13.83 | 468.0K | 33,836 | — | ↗ |
| 2021-05-27 | Kapadia Sandip | Director | A-Award | A | Director Stock Option (Right to Buy) | 16,918 | 13.83 | 234.0K | 16,918 | — | ↗ |
| 2021-05-27 | Islam Saqib | Director | A-Award | A | Director Stock Option (Right to Buy) | 16,918 | 13.83 | 234.0K | 16,918 | — | ↗ |
| 2021-05-27 | GOWEN MAXINE | Director | A-Award | A | Director Stock Option (Right to Buy) | 4,542 | 13.83 | 62.8K | 4,542 | — | ↗ |
| 2021-05-27 | Countouriotis Athena | Director | A-Award | A | Director Stock Option (Right to Buy) | 16,918 | 13.83 | 234.0K | 16,918 | — | ↗ |
| 2021-05-21 | Morris Richard Steven | Officer | P-Purchase | A | Common Stock | 2,171 | 13.82 | 30.0K | 5,454 | — | ↗ |
| 2021-05-21 | Goldsmith Bruce A | Director / Officer | P-Purchase | A | Common Stock | 2,000 | 13.12 | 26.2K | 5,983 | — | ↗ |
| 2021-05-17 | Fotopoulos Alexandros | Officer | A-Award | A | Restricted Stock Unit (RSU) | 50,000 | 0.00 | — | 50,000 | — | ↗ |
| 2021-03-22 | Salinas Eliseo Oreste | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2021-03-15 | Romano Gary | Officer | M-Exempt | D | Employee Stock Option (right to buy) | 10,000 | 8.07 | 80.7K | 300,821 | — | ↗ |
| 2021-02-18 | GOWEN MAXINE | Director | A-Award | A | Stock Option (right to buy) | 33,836 | 21.46 | 726.1K | 33,836 | — | ↗ |
| 2021-02-16 | Romano Gary | Officer | A-Award | A | Stock Option (right to buy) | 105,000 | 21.85 | 2.29M | 105,000 | — | ↗ |
| 2021-02-16 | Quigley Jill M. | Officer | A-Award | A | Stock Option (right to buy) | 105,000 | 21.85 | 2.29M | 105,000 | — | ↗ |
| 2021-02-16 | Morris Richard Steven | Officer | A-Award | A | Stock Option (right to buy) | 50,000 | 21.85 | 1.09M | 50,000 | — | ↗ |
| 2021-02-16 | Goldsmith Bruce A | Director / Officer | A-Award | A | Stock Option (right to buy) | 262,000 | 21.85 | 5.72M | 262,000 | — | ↗ |
| 2021-02-16 | Fotopoulos Alexandros | Officer | A-Award | A | Stock Option (right to buy) | 105,000 | 21.85 | 2.29M | 105,000 | — | ↗ |
| 2021-02-16 | Cale Edgar B. | Officer | A-Award | A | Stock Option (right to buy) | 170,997 | 21.85 | 3.74M | 170,997 | — | ↗ |
| 2021-01-20 | Quigley Jill M. | Officer | S-Sale | D | Common Stock | 1,300 | 30.01 | 39.0K | 295,284 | — | ↗ |
| 2021-01-14 | Quigley Jill M. | Officer | S-Sale | A | Common Stock | 16,298 | 30.10 | 490.6K | 296,584 | — | ↗ |
| 2020-03-24 | Countouriotis Athena | Director | P-Purchase | A | Common Stock | 10,000 | 14.98 | 149.8K | 18,900 | — | ↗ |
| 2020-03-03 | Yamada Tadataka | Director | P-Purchase | A | Common Stock | 6,500 | 18.00 | 117.0K | 656,149 | — | ↗ |
| 2020-03-03 | Woiwode Thomas | Director / 10% Owner | C-Conversion | A | Common Stock | 708,352 | 0.00 | — | 708,352 | — | ↗ |
| 2020-03-03 | Versant Venture Capital VI, L.P. | 10% Owner | C-Conversion | A | Common Stock | 1,049,175 | 0.00 | — | 4,026,417 | — | ↗ |
| 2020-03-03 | Ratcliffe Liam | Director | P-Purchase | A | Common Stock | 2,800 | 18.00 | 50.4K | 2,800 | — | ↗ |
| 2020-03-03 | Quigley Jill M. | Officer | P-Purchase | A | Common Stock | 1,000 | 18.00 | 18.0K | 1,000 | — | ↗ |
| 2020-03-03 | ORBIMED ADVISORS LLC | 10% Owner | C-Conversion | A | Common Stock | 541,002 | 0.00 | — | 5,947,323 | — | ↗ |
| 2020-03-03 | Morris Richard Steven | Officer | P-Purchase | A | Common Stock | 400 | 18.00 | 7.2K | 400 | — | ↗ |
| 2020-03-03 | Kapadia Sandip | Director | P-Purchase | A | Common Stock | 5,000 | 18.00 | 90.0K | 5,000 | — | ↗ |
| 2020-03-03 | Islam Saqib | Director | P-Purchase | A | Common Stock | 5,000 | 18.00 | 90.0K | 5,000 | — | ↗ |
| 2020-03-03 | Heron Patrick J | Director / 10% Owner | C-Conversion | A | Common Stock | 2,977,242 | 0.00 | — | 2,977,242 | — | ↗ |
| 2020-03-03 | Goldsmith Bruce A | Director / Officer | P-Purchase | A | Common Stock | 1,100 | 18.00 | 19.8K | 1,100 | — | ↗ |
| 2020-03-03 | Frazier Life Sciences IX, L.P. | 10% Owner | C-Conversion | A | Common Stock | 432,802 | 0.00 | — | 4,459,219 | — | ↗ |
| 2020-03-03 | Fotopoulos Alexandros | Officer | P-Purchase | A | Common Stock | 5,500 | 18.00 | 99.0K | 5,500 | — | ↗ |
| 2020-03-03 | Countouriotis Athena | Director | P-Purchase | A | Common Stock | 8,900 | 18.00 | 160.2K | 8,900 | — | ↗ |
| 2020-03-03 | Cale Edgar B. | Officer | P-Purchase | A | Common Stock | 2,000 | 18.00 | 36.0K | 2,000 | — | ↗ |
| 2020-02-28 | ORBIMED ADVISORS LLC | 10% Owner | P-Purchase | A | Common Stock | 373,300 | 18.00 | 6.72M | 373,300 | — | ↗ |
| 2020-02-27 | Yamada Tadataka | Director | — | D | Common Stock | 0 | 0.00 | — | 649,649 | — | ↗ |
| 2020-02-27 | Woiwode Thomas | Director / 10% Owner | — | I | Series B Preferred Stock | 708,352 | 0.00 | — | 0 | — | ↗ |
| 2020-02-27 | Versant Venture Capital VI, L.P. | 10% Owner | — | D | Series A-1 Preferred Stock | 2,977,242 | 0.00 | — | 0 | — | ↗ |
| 2020-02-27 | SQUINTO STEPHEN P | Director / Officer | — | D | Common Stock | 0 | 0.00 | — | 668,575 | — | ↗ |
| 2020-02-27 | Romano Gary | Officer | — | D | Employee Stock Option (Right to Buy) | 54,850 | 11.00 | 603.4K | 0 | — | ↗ |
| 2020-02-27 | Ratcliffe Liam | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2020-02-27 | Quigley Jill M. | Officer | — | D | Common Stock | 0 | 0.00 | — | 309,994 | — | ↗ |
| 2020-02-27 | ORBIMED ADVISORS LLC | 10% Owner | — | I | Series B Preferred Stock | 541,002 | 0.00 | — | 0 | — | ↗ |
| 2020-02-27 | Morris Richard Steven | Officer | — | D | Employee Stock Option (Right to Buy) | 310,821 | 8.07 | 2.51M | 0 | — | ↗ |
| 2020-02-27 | Kapadia Sandip | Director | — | D | Director Stock Option (Right to Buy) | 63,992 | 11.00 | 703.9K | 0 | — | ↗ |
| 2020-02-27 | Islam Saqib | Director | — | D | Director Stock Option (Right to Buy) | 82,221 | 8.07 | 663.5K | 0 | — | ↗ |
| 2020-02-27 | Heron Patrick J | Director / 10% Owner | — | I | Series A-2 Preferred Stock | 1,049,175 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
3.21M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | William Chou, M.D. President, Chief Executive Officer and Director | 661.0K | — | 234.0K | 239.3K | 335.0K | 17.5K | 1.49M | 31.83% | ↗ |
| 2 | 2025 | Kathleen Borthwick Chief Financial Officer | 450.6K | — | 117.0K | 85.4K | 181.3K | 17.5K | 851.8K | 23.77% | ↗ |
| 3 | 2025 | Edgar B. (Chip) Cale General Counsel and Corporate Secretary | 221.9K | — | 197.1K | 156.9K | — | 17.5K | 593.3K | 59.66% | ↗ |
| 4 | 2024 | William Chou, M.D. President, Chief Executive Officer and Director | 638.5K | — | — | 646.7K | 334.4K | 17.3K | 1.64M | 39.51% | ↗ |
| 5 | 2024 | Edgar B. (Chip) Cale General Counsel and Corporate Secretary | 436.8K | — | — | 255.1K | 172.8K | 17.3K | 881.9K | 28.93% | ↗ |
| 6 | 2024 | Kathleen Borthwick Chief Financial Officer | 420.7K | — | — | 257.0K | 166.8K | 17.3K | 861.7K | 29.82% | ↗ |
| 7 | 2023 | William Chou, M.D. President, Chief Executive Officer and Director | 599.2K | — | — | 502.8K | 330.0K | 16.5K | 1.45M | 34.71% | ↗ |
| 8 | 2023 | Alex Fotopoulos Former Chief Technical Officer | 315.8K | — | — | 145.0K | — | 840.1K | 1.30M | 11.15% | ↗ |
| 9 | 2023 | Simona King Former Chief Financial Officer | 304.5K | — | — | 116.0K | — | 691.9K | 1.11M | 10.43% | ↗ |
| 10 | 2023 | Mark Forman, M.D., Ph.D. Chief Medical Officer | 462.2K | 200.0K | — | 145.0K | 187.6K | 16.5K | 1.01M | 14.34% | ↗ |
| 11 | 2023 | Edgar B. (Chip) Cale General Counsel and Corporate Secretary | 420.0K | 200.0K | — | 145.0K | 168.2K | 16.5K | 949.7K | 15.27% | ↗ |
| 12 | 2022 | Bruce Goldsmith, Ph.D. Former President and Chief Executive Officer | 297.7K | — | — | 1.00M | — | 1.33M | 2.63M | 38.17% | ↗ |
| 13 | 2022 | Alex Fotopoulos Chief Technical Officer | 463.5K | — | 66.5K | 914.6K | 176.9K | 13.6K | 1.64M | 60.00% | ↗ |
| 14 | 2022 | Alex Fotopoulos Former Chief Technical Officer | 463.5K | — | 66.5K | 914.6K | 176.9K | 13.6K | 1.64M | 60.00% | ↗ |
| 15 | 2022 | Monika (Maria) Toernsen Former Chief Commercial Officer | 439.3K | — | — | 527.5K | — | 659.7K | 1.63M | 32.43% | ↗ |
| 16 | 2022 | Simona King Chief Financial Officer | 454.8K | — | 131.8K | 829.2K | 162.0K | 16.1K | 1.59M | 60.29% | ↗ |
| 17 | 2022 | Simona King Former Chief Financial Officer | 454.8K | — | 131.8K | 829.2K | 162.0K | 16.1K | 1.59M | 60.29% | ↗ |
| 18 | 2022 | Edgar B. (Chip) Cale General Counsel and Former Interim Chief Executive Officer | 508.1K | — | 66.5K | 682.9K | 149.4K | 16.9K | 1.42M | 52.64% | ↗ |
| 19 | 2022 | Edgar B. (Chip) Cale General Counsel and Corporate Secretary | 508.1K | — | 66.5K | 682.9K | 149.4K | 16.9K | 1.42M | 52.64% | ↗ |
| 20 | 2022 | William Chou, M.D. President and Chief Executive Officer | 111.5K | 200.0K | — | 900.7K | 72.0K | 11.9K | 1.30M | 69.49% | ↗ |
| 21 | 2022 | William Chou, M.D. President, Chief Executive Officer and Director | 111.5K | 200.0K | — | 900.7K | 72.0K | 11.9K | 1.30M | 69.49% | ↗ |
| 22 | 2021 | Eliseo Salinas, M.D. Former Chief of Research and Development | 357.9K | 100.0K | 1.89M | 4.07M | 132.9K | 969.00 | 6.55M | 90.97% | ↗ |
| 23 | 2021 | Bruce Goldsmith, Ph.D. Former President and Chief Executive Officer | 550.0K | — | — | 4.48M | 242.0K | 15.6K | 5.29M | 84.73% | ↗ |
| 24 | 2021 | Bruce Goldsmith, Ph.D. Chief Executive Officer and President | 550.0K | — | — | 4.48M | 242.0K | 15.6K | 5.29M | 84.73% | ↗ |
| 25 | 2021 | Jill Quigley Former Chief Operating Officer | 453.4K | — | — | 1.80M | 204.0K | 1.14M | 3.59M | 50.03% | ↗ |
| 26 | 2021 | Simona King Chief Financial Officer | 151.4K | — | — | 3.23M | 144.5K | 2.1K | 3.53M | 91.57% | ↗ |
| 27 | 2021 | Edgar B. (Chip) Cale General Counsel and Former Interim Chief Executive Officer | 390.0K | — | — | 2.92M | 130.7K | 18.5K | 3.46M | 84.44% | ↗ |
| 28 | 2021 | Alex Fotopoulos Chief Technical Officer | 413.8K | — | 741.0K | 1.80M | 151.0K | 18.7K | 3.12M | 81.31% | ↗ |
| 29 | 2021 | Monika (Maria) Toernsen Former Chief Commercial Officer | 192.1K | 50.0K | 260.8K | 2.03M | 144.5K | 4.5K | 2.68M | 85.40% | ↗ |
| 30 | 2020 | Bruce Goldsmith, Ph.D. Chief Executive Officer and President | 450.0K | — | — | 15.99M | 258.8K | 12.6K | 16.71M | 95.68% | ↗ |
| 31 | 2020 | Jill Quigley Former Chief Operating Officer | 431.8K | — | — | 3.39M | 203.0K | 362.9K | 4.39M | 77.26% | ↗ |
| 32 | 2020 | Jill Quigley Chief Operating Officer | 431.8K | — | — | 3.39M | 203.0K | 362.9K | 4.39M | 77.26% | ↗ |
| 33 | 2020 | Stephen Squinto, Ph.D. Former Interim Chief Executive Officer and former Acting Head of Research and Development | 246.0K | — | — | 2.98M | — | 541.0K | 3.76M | 79.10% | ↗ |
| 34 | 2020 | Gary Romano, M.D., Ph.D. Chief Medical Officer | 416.3K | 107.4K | — | 1.47M | 191.5K | 14.3K | 2.20M | 66.82% | ↗ |
| 35 | 2019 | Stephen Squinto, Ph.D. Former Interim Chief Executive Officer and former Acting Head of Research and Development | 225.0K | — | — | 1.79M | 127.4K | — | 2.14M | 83.54% | ↗ |
| 36 | 2019 | Gary Romano, M.D., Ph.D. Chief Medical Officer | 111.1K | — | — | 1.86M | 49.1K | 2.3K | 2.02M | 91.97% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| William Chou | President, Chief Executive Officer & Director | 1M | — |
| Kathleen Borthwick | Senior Vice President, Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer | 649.4K | female |
| Eden Fucci | Senior Vice President of Technical Operations | — | male |
| Karl Whitney | Senior Vice President of Global Regulatory Affairs | — | — |
| Stuart Henderson | Chief Business Officer | — | male |
| Sue Browne | Chief Scientific Officer | — | — |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PASG
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
